Colinz Lab Peer Comparison

BSE: 531210

₹76.20

₹1.20 (1.60%)

As on 25-Sep-2026IST

Market cap

₹19 Cr

Revenue (TTM)

₹6 Cr

P/E Ratio

6.9

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	19	36,827	27,985	27,762	26,788
Revenue (₹ Cr)	6	3,564	9,205	1,936	1,462
Net Profit (₹ Cr)	2.80	414.00	-371.81	288.22	387.35
Net Margin (%)	44.08	11.23	-3.93	14.79	26.01
RoE (%)	5.10	8.38	-3.85	29.77	25.18
Price to Earnings	6.87	90.04	--	96.32	69.36
Price-To-Book	1.54	7.32	3.50	20.68	15.53

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	5.81	3,564.00	9,205.28	1,935.80	1,461.80
Total Income	6.34	3,686.00	9,449.59	1,948.58	1,489.25
Total Expenditure	5.48	2,792.00	8,195.15	1,485.56	919.25
EBITDA	0.33	772.00	1,010.13	450.24	542.56
Depreciation	0.16	226.00	857.51	50.83	37.68
EBIT	0.18	546.00	152.62	399.41	504.88
Interest	0.04	217.00	342.73	40.84	3.77
Other Income	0.53	122.00	244.31	12.78	27.45
Exceptional Items	2.76	12.00	-216.88	0.00	0.00
Profit before Tax	3.43	463.00	-162.68	371.35	528.56
Provision for Tax	0.63	49.00	209.13	83.14	141.21
Profit after Tax	2.80	414.00	-371.81	288.22	387.35

Liabilities (₹ Cr)

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	10.04	4,940.00	8,162.62	1,288.82	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	0.17	1,712.00	5,044.14	202.03	42.40
Current Liabilities	2.57	1,622.00	4,758.28	835.87	230.82
Total Liabilities	12.78	8,578.00	17,723.32	2,326.71	1,983.96

Assets (₹ Cr)

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	2.65	5,343.00	10,211.52	519.60	1,026.85
Current Assets	10.08	2,606.00	7,191.66	1,681.81	881.27
Total Assets	12.78	8,578.00	17,723.32	2,326.71	1,983.96
Total Debt*	0.39	2,125.00	5,495.48	259.37	26.49
Net Current Assets	7.51	984.00	2,433.38	845.94	650.46
Contingent Liabilities	--	768.26	95.72	19.09	17.25

Cashflow (₹ Cr)

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	2.54	390.00	1,652.60	205.05	292.17
Cash Flow from Investing Activities	0.01	-241.00	-826.03	-409.72	-265.94
Cash from Financing Activities	0.43	-54.00	-38.98	283.07	4.10
Net Cash Inflow / Outflow	2.98	95.00	787.59	78.39	30.33

Ratios

Profitability Ratios

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	7.16	6.79	1.24	29.22	32.42
ROE (%)	5.10	8.38	-3.85	29.77	25.18
ROA (%)	22.73	4.94	-2.21	24.77	21.93
EBIT Margin (%)	3.06	15.32	1.66	20.63	34.54
Net Margin (%)	44.08	11.23	-3.93	14.79	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	-8.43	18.37	0.78	46.65	40.90
EBIT Growth (%)	-46.71	252.26	-70.53	62.13	124.50
Net Profit Growth (%)	484.73	377.85	-1,383.43	89.49	104.15
EPS Growth (%)	6.32	1,001.33	-484.84	78.60	42.32
Book Value Growth (%)	6.00	13.47	0.33	144.31	26.03

Valuation Ratios

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	37.77	92.42	-89.43	94.85	69.36
Price / Book Value	1.54	7.32	3.50	20.68	15.53
Dividend Yield (%)	0.00	0.00	0.00	0.09	0.08
EV/EBITDA	33.10	49.60	31.80	61.47	49.01
Market Cap (₹ Cr)	11.21	19,071.62	18,108.89	12,753.19	20,944.75

Solvency Ratios

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	0.00	0.31	0.53	0.11	0.02
Short term debt to equity ratio	0.04	0.09	0.09	0.05	0.02
Current Ratio	3.93	1.61	1.51	2.01	3.82
Quick Ratio	3.65	1.06	0.87	1.14	2.82
Interest Coverage	82.64	3.13	0.53	10.09	141.16

Operating Efficiency Ratios

	Colinz Lab	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	14.37	16.50	23.44	26.28	24.80
Asset Turnover	0.47	0.43	0.55	1.66	0.83
Receivable days	44.49	58.75	78.20	40.13	88.98
Inventory Days	44.15	75.82	93.30	60.29	56.04
Payable days	98.78	186.21	226.14	232.47	99.95
Cash Conversion Cycle	-10.13	-51.64	-54.64	-132.04	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly